Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.98 |
| ▸ | BCHE | P06276 | 15/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tianeptine SCHEMBL1231001 | 1.00 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL3996165 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29930593 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29877330 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29470274 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL49293 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL2894680 | 0.98 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| SCHEMBL4262606 | 0.98 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL20338621 | 0.97 | NR1I2 (0.96) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Hydrochloric Acid SCHEMBL22664293 | 0.97 | NR1I2 (0.96) | NR1I2OPRM1DRD3OPRD1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198268-B2 | Tianeptine sulfate salt forms and methods of making and using the same | JANSSEN BIOTECH, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| WO-2010051239-A1 | TIANEPTINE SULFATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100112051-A1 | TIANEPTINE SULFATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | JANSSEN BIOTECH, INC. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112051-A1 | TIANEPTINE SULFATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | NPSR1, CRH, OPRL1 | NR1I2 1217/4885OPRM1 105/4885DRD3 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.